Eledon Pharmaceuticals, Inc. Common Stock
ELDNEledon Pharmaceuticals, Inc. (ELDN) is a biotechnology company focused on developing novel therapies for inflammatory and neurodegenerative diseases. The company's lead programs target conditions such as amyotrophic lateral sclerosis (ALS) and organ transplant rejection, utilizing its proprietary Elededril platform to modulate the immune system and improve patient outcomes.
Company News
Eledon Pharmaceuticals reported positive Phase 2 BESTOW trial results for tegoprubart, demonstrating favorable safety in kidney transplant prevention, and raised $57.5 million in financing to advance transplantation programs.
Eledon Pharmaceuticals announced positive Phase 2 trial results for tegoprubart, a potential new immunosuppression treatment for kidney transplant patients, showing promising safety and efficacy with reduced side effects compared to tacrolimus.
Eledon Pharmaceuticals will present topline results from its Phase 2 BESTOW trial evaluating tegoprubart for kidney transplant rejection prevention at the American Society of Nephrology's Kidney Week 2025 in Houston, TX.
Eledon Pharmaceuticals' CEO will participate in a fireside chat at the Cantor Global Healthcare Conference, discussing the company's investigational product tegoprubart, an anti-CD40L antibody targeting immune-modulating therapies for conditions like kidney transplantation and ALS.
The global renal transplant therapeutics market is projected to grow significantly by 2032, driven by increasing kidney disease prevalence, advanced research, and innovative therapies to prevent transplant rejection.
